common.study.topics.clinical

Nanovectors to Prevent Placental Passage of Tocolytic Agents

common.study.values.description

Nanovectors to Prevent Placental Passage of Tocolytic Agents

The purpose of the study is to find out whether indomethacin encapsulated within a nanovector can stop contractions in pregnant human uterine tissue. Preterm delivery is a major contributor to newborn deaths. The treatment of preterm labor includes medications that stop contractions within the uterus, or womb. Indomethacin is effective in stopping uterine contractions, but crosses the placenta to the unborn baby causing problems for the baby. Nanovectors are used to direct the delivery of medications. If indomethacin can be delivered directly to the uterus using a nanovector, it may be an ideal medication to treat preterm labor. We hypothesize that nanovectors loaded with indomethacin will reduce uterine contractions.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

No pharmaceutical medication involved common.study.methods.has-drugs-no
Patients and healthy individuals accepted common.study.methods.is-healthy-no

common.study.methods.no-methods

participant.views.study.view.additional

participant.views.study.view.scientific-title

Development of Nanovectors to Prevent Placental Passage of a Tocolytic Agent

common.study.values.clinical-trial-id

NCT02199756

participant.views.study.view.id

qaQOqd